Skip to main content
Top
Published in: Clinical Pharmacokinetics 4/2010

01-04-2010 | Short Communication

Prediction of Propofol Clearance in Children from an Allometric Model Developed in Rats, Children and Adults versus a 0.75 Fixed-Exponent Allometric Model

Authors: Mariska Y. M. Peeters, Karel Allegaert, Heleen J. Blussé van Oud-Alblas, Massimo Cella, Dick Tibboel, Meindert Danhof, Dr Catherijne A. J. Knibbe

Published in: Clinical Pharmacokinetics | Issue 4/2010

Login to get access

Abstract

Background and Objective: For propofol clearance, allometric scaling has been applied successfully for extrapolations between species (rats and humans) and within the human bodyweight range (children and adults). In this analysis, the human bodyweight range is explored to determine for which range an allometric model with a fixed or estimated exponent can be used to predict propofol clearance, without correction for maturation.
Methods: The predictive value of the allometric equation, clearance (CL) is equal to 0.071 × bodyweight in kg0.78, which was developed from rats, children and adults, and the predictive value of a fixed exponent allometric model derived from the basal metabolic rate, CL is equal to CL standardized to a 70 kg adult × (bodyweight in kg standardized to a 70 kg adult)0.75, were evaluated across five independent patient groups including (i) 25 (pre)term neonates with a postmenstrual age of 27–43 weeks; (ii) 22 postoperative infants aged 4–18 months; (iii) 12 toddlers aged 1–3 years; (iv) 14 adolescents aged 10–20 years; and (v) 26 critically ill adults sedated long term. The median percentage error of the predictions was calculated using the equation %error = (CLallometric − CLi)/CLi × 100, where CLallometric is the predicted propofol clearance from the allometric equations for each individual and CLi is the individual-predicted (post hoc) propofol clearance value derived from published population pharmacokinetic models.
Results: In neonates, the allometric model developed from rats, children and adults, and the fixed-exponent allometric model, systematically overpredicted individual propofol clearance, with median percentage errors of 288% and 216%, respectively, whereas in infants, both models systematically underpredicted individual propofol clearance, with median percentage errors of −43% and −55%, respectively. In toddlers, adolescents and adults, both models performed reasonably well, with median percentage errors of −12% and–32%, respectively, in toddlers, 16% and −14%, respectively, in adolescents, and 12% and −18%, respectively, in adults.
Conclusion: Both allometric models based on bodyweight alone may be of use to predict propofol clearance in individuals older than 2 years. Approaches that also incorporate maturation are required to predict clearance under the age of 2 years.
Literature
1.
go back to reference Kleiber M. Body size and metabolism. Hilgardia 1932; 6: 315 Kleiber M. Body size and metabolism. Hilgardia 1932; 6: 315
2.
go back to reference West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276(5309): 122–6PubMedCrossRef West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276(5309): 122–6PubMedCrossRef
3.
go back to reference Glazier DS. Beyond the ‘3/4-power law’: variation in the intra- and interspecific scaling of metabolic rate in animals. Biol Rev Camb Philos Soc 2005; 80(4): 611–62PubMedCrossRef Glazier DS. Beyond the ‘3/4-power law’: variation in the intra- and interspecific scaling of metabolic rate in animals. Biol Rev Camb Philos Soc 2005; 80(4): 611–62PubMedCrossRef
4.
go back to reference Packard GC, Birchard GF. Traditional allometric analysis fails to provide a valid predictive model for mammalian metabolic rates. J Exp Biol 2008; 211 (Pt22): 3581–7CrossRef Packard GC, Birchard GF. Traditional allometric analysis fails to provide a valid predictive model for mammalian metabolic rates. J Exp Biol 2008; 211 (Pt22): 3581–7CrossRef
5.
go back to reference White CR, Cassey P, Blackburn TM. Allometric exponents do not support a universal metabolic allometry. Ecology 2007; 88(2): 315–23PubMedCrossRef White CR, Cassey P, Blackburn TM. Allometric exponents do not support a universal metabolic allometry. Ecology 2007; 88(2): 315–23PubMedCrossRef
6.
7.
go back to reference Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008; 101(5): 680–9PubMedCrossRef Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008; 101(5): 680–9PubMedCrossRef
8.
go back to reference Anderson BJ, Pons G, Autret-Leca E, et al. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr Anaesth 2005; 15(4): 282–92PubMedCrossRef Anderson BJ, Pons G, Autret-Leca E, et al. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr Anaesth 2005; 15(4): 282–92PubMedCrossRef
9.
go back to reference Cox EH, Knibbe CA, Koster VS, et al. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res 1998; 15(3): 442–8PubMedCrossRef Cox EH, Knibbe CA, Koster VS, et al. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res 1998; 15(3): 442–8PubMedCrossRef
10.
go back to reference Knibbe CA, Melenhorst-de Jong G, Mestrom M, et al. Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol 2002; 54(4): 415–22PubMedCrossRef Knibbe CA, Melenhorst-de Jong G, Mestrom M, et al. Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol 2002; 54(4): 415–22PubMedCrossRef
11.
go back to reference Knibbe CA, Aarts LP, Kuks PF, et al. Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. Eur J Clin Pharmacol 2000; 56: 89–95PubMedCrossRef Knibbe CA, Aarts LP, Kuks PF, et al. Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. Eur J Clin Pharmacol 2000; 56: 89–95PubMedCrossRef
12.
go back to reference Knibbe CA, Zuideveld KP, Aarts LP, et al. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol 2005; 59(6): 705–11PubMedCrossRef Knibbe CA, Zuideveld KP, Aarts LP, et al. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol 2005; 59(6): 705–11PubMedCrossRef
13.
go back to reference Allegaert K, Peeters MY, Verbesselt R, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth 2007; 99(6): 864–70PubMedCrossRef Allegaert K, Peeters MY, Verbesselt R, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth 2007; 99(6): 864–70PubMedCrossRef
14.
go back to reference Peeters MY, Prins SA, Knibbe CA, et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 2006; 104(3): 466–74PubMedCrossRef Peeters MY, Prins SA, Knibbe CA, et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 2006; 104(3): 466–74PubMedCrossRef
15.
go back to reference Murat I, Billard V, Vernois J, et al. Pharmacokinetics of propofol after a single dose in children aged 1–3 years with minor burns: comparison of three data analysis approaches. Anesthesiology 1996; 84(3): 526–32PubMedCrossRef Murat I, Billard V, Vernois J, et al. Pharmacokinetics of propofol after a single dose in children aged 1–3 years with minor burns: comparison of three data analysis approaches. Anesthesiology 1996; 84(3): 526–32PubMedCrossRef
16.
go back to reference Peeters MY, Bras LJ, DeJongh J, et al. Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther 2008; 83(3): 443–51PubMedCrossRef Peeters MY, Bras LJ, DeJongh J, et al. Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther 2008; 83(3): 443–51PubMedCrossRef
17.
go back to reference Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: amulticenter study. Anesthesiology 2000; 92(3): 727–38PubMedCrossRef Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: amulticenter study. Anesthesiology 2000; 92(3): 727–38PubMedCrossRef
18.
go back to reference Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006; 61(5): 545–57PubMedCrossRef Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006; 61(5): 545–57PubMedCrossRef
19.
go back to reference Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303–32PubMedCrossRef Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303–32PubMedCrossRef
20.
go back to reference Knibbe CA, Krekels EHJ, Van Den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009; 48(6): 371–85PubMedCrossRef Knibbe CA, Krekels EHJ, Van Den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009; 48(6): 371–85PubMedCrossRef
21.
go back to reference Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47(4): 231–43PubMedCrossRef Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47(4): 231–43PubMedCrossRef
Metadata
Title
Prediction of Propofol Clearance in Children from an Allometric Model Developed in Rats, Children and Adults versus a 0.75 Fixed-Exponent Allometric Model
Authors
Mariska Y. M. Peeters
Karel Allegaert
Heleen J. Blussé van Oud-Alblas
Massimo Cella
Dick Tibboel
Meindert Danhof
Dr Catherijne A. J. Knibbe
Publication date
01-04-2010
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 4/2010
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/11319350-000000000-00000

Other articles of this Issue 4/2010

Clinical Pharmacokinetics 4/2010 Go to the issue